Ono Pharma Gets in Licensing Agreement for NXI-101

Ono Pharma inks licensing agreement with NEX-I to develop and commercialize NXI-101

Ono Pharmaceutical Co., Ltd., company develops novel therapeutics to help patients live longer, healthier lives, announced that it has entered into a license agreement with NEX-I, Inc. for NXI-101.

About NXI-101

NXI-101 is a first-in-class antibody drug candidate targeting ONCOKINE-1, which is a cancer immunotherapy-resistant factor discovered by NEX-I through its proprietary target screening platform “ONCOKINE platform”. It has a potential to be a novel antibody drug with an efficacy against multiple cancer types including cancer immunotherapy-resistant cancer.

Agreement Terms

• Under the terms of this agreement, Ono will have an exclusive right to develop and commercialize NXI-101 and its backup antibodies worldwide. 
• Ono will pay to NEX-I an up-front and milestone payments on the progress of development and commercialization, as well as tiered royalties based on net sales.

Statement from Ono

“We are pleased to collaborate with NEX-I having a proprietary ONCOKINE platform for development and commercialization of NXI-101. We expect NXI-101 to be a new treatment option for cancer patients,” said Toichi Takino, senior executive officer/executive director, discovery & research of Ono. “Leveraging Ono's experience and expertise in cancer immunotherapy, we will work on the development of the compound to add it to our development pipeline in oncology.""

Words from CEO: NEX-I

“We are delighted to start a journey with Ono, a leader in cancer immunotherapy well-known for its breakthrough anti-PD-1 antibody. This collaboration aligns with NEX-I’s strategic focus on novel target discovery and the advancement of our flagship tumour microenvironment modulator, NXI-101. Through this landmark partnership, we underscore our commitment to identifying and developing novel and differentiated therapies that promise substantial benefits for patients,” said Kyoung Wan Yoon, Ph.D., chief executive officer of NEX-I. “Our alliance with Ono represents a significant step forward for our ONCOKINE platform to assemble a diverse portfolio of clinical candidates across a broad range of mechanisms and therapeutic targets.”

About NEX-I

• Founded in 2021, NEX-I, Inc. is a pre-clinical stage Korean biotechnology company pioneering the transformative shift in cancer immunotherapy through its proprietary novel target discovery platform. 
• NEX-I identifies and counters conventional treatments often facing resistance from evolving cancer cells, and they set new standards to understand the mechanisms of refractory cancers by targeting the causal factors. 
• With their premier monoclonal antibody, NXI-101, which is designed to modulate the tumour microenvironment by neutralizing the ONCOKINE-1, increasing immune susceptibility of the cancer patients can be expected.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!